Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY R&D Tax Credit Overhaul Likely in FY2017, but In a Way to Spur Investments: LDP’s Goto
February 4, 2015
-
BUSINESS Wave of Downsizing (2): Job Cuts at Non-Japanese Makers Also Come to Fore
February 4, 2015
-
BUSINESS Wave of Downsizing (1): Major Japan Drug Makers Offer Voluntary Redundancies
February 3, 2015
-
BUSINESS Over 500 Daiichi Sankyo Employees Take Voluntary Redundancy
February 2, 2015
-
REGULATORY Drug Discovery Support Project for Academia to Receive 3-Fold Budget Increase in FY2015
January 30, 2015
-
BUSINESS Chugai Sales Grow 8.8% Thanks to Increasing Actemra Exports
January 29, 2015
-
BUSINESS PD-1, PD-L1 Inhibitors Could Carve Out 750 Billion Yen Market in Japan: Citi Analyst
January 28, 2015
-
BUSINESS Cost of Producing Antibody Drugs Remains High Despite Improvement in Culture Efficiency: Kyowa Kirin
January 27, 2015
-
REGULATORY Japan-Version Compassionate Use May Cover Drugs with No Approval Globally
January 26, 2015
-
REGULATORY Chuikyo’s HTA Panel to Hold Closed Meeting on Jan. 28
January 23, 2015
-
BUSINESS Open Tenders Good Example of Early Price Settlements: Qol Exec
January 22, 2015
-
ORGANIZATION Some LDP Members Keen to Tackle Kampo NHI Price Problem
January 21, 2015
-
REGULATORY R&D Tax Credit Revamp (2): No Deadline Set, yet Revision Could Come Up for Debate towards FY2017
January 21, 2015
-
REGULATORY R&D Tax Credit Revamp (1): New Scheme for Open Innovation Research Significant in 3 Ways
January 20, 2015
-
REGULATORY PMDA Head Expresses Full Support for AMED
January 19, 2015
-
ORGANIZATION JPMA Notifies of Unfavorable Expressions for Disease Awareness Ads
January 16, 2015
-
ORGANIZATION Pharma Leader Nakayama Hails Tax Plan, Says His New Year Remarks Misleading
January 15, 2015
-
INTERVIEW EFPIA Japan Chairman Says Drug Costs Won’t Explode
January 14, 2015
-
ORGANIZATION Wholesalers Must Revamp Biz Model to Cope with Change in Sales Mix: JPWA Chief
January 14, 2015
-
REGULATORY MHLW Calls for Revision of Package Inserts for SGLT-2 Inhibitors
January 13, 2015
ページ
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel on November 28 agreed on a plan to legally require pharma companies to set up…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…